OR4D2

Across TCGA pan-cancer cohorts, OR4D2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR4D2 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher OR4D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4D2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, LUSC, and SCLC are the cancer types where OR4D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	OS	Median	All	0.296	0.665	<.001	18	view →
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	1.000	0.213	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR4D2–THYM (OS)

Open the THYM breakdown →